1. Home
  2. SNGX vs CPHI Comparison

SNGX vs CPHI Comparison

Compare SNGX & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNGX
  • CPHI
  • Stock Information
  • Founded
  • SNGX 1987
  • CPHI N/A
  • Country
  • SNGX United States
  • CPHI China
  • Employees
  • SNGX N/A
  • CPHI N/A
  • Industry
  • SNGX Biotechnology: Pharmaceutical Preparations
  • CPHI Biotechnology: Pharmaceutical Preparations
  • Sector
  • SNGX Health Care
  • CPHI Health Care
  • Exchange
  • SNGX Nasdaq
  • CPHI Nasdaq
  • Market Cap
  • SNGX 6.5M
  • CPHI 7.3M
  • IPO Year
  • SNGX 1987
  • CPHI N/A
  • Fundamental
  • Price
  • SNGX $1.37
  • CPHI $1.83
  • Analyst Decision
  • SNGX
  • CPHI
  • Analyst Count
  • SNGX 0
  • CPHI 0
  • Target Price
  • SNGX N/A
  • CPHI N/A
  • AVG Volume (30 Days)
  • SNGX 147.3K
  • CPHI 152.1K
  • Earning Date
  • SNGX 08-08-2025
  • CPHI 08-13-2025
  • Dividend Yield
  • SNGX N/A
  • CPHI N/A
  • EPS Growth
  • SNGX N/A
  • CPHI N/A
  • EPS
  • SNGX N/A
  • CPHI N/A
  • Revenue
  • SNGX $2,342.00
  • CPHI $4,295,377.00
  • Revenue This Year
  • SNGX N/A
  • CPHI N/A
  • Revenue Next Year
  • SNGX N/A
  • CPHI N/A
  • P/E Ratio
  • SNGX N/A
  • CPHI N/A
  • Revenue Growth
  • SNGX N/A
  • CPHI N/A
  • 52 Week Low
  • SNGX $1.31
  • CPHI $1.20
  • 52 Week High
  • SNGX $14.83
  • CPHI $3.35
  • Technical
  • Relative Strength Index (RSI)
  • SNGX 23.71
  • CPHI 52.11
  • Support Level
  • SNGX $1.31
  • CPHI $1.55
  • Resistance Level
  • SNGX $1.95
  • CPHI $1.91
  • Average True Range (ATR)
  • SNGX 0.07
  • CPHI 0.18
  • MACD
  • SNGX -0.05
  • CPHI 0.02
  • Stochastic Oscillator
  • SNGX 9.56
  • CPHI 61.38

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About CPHI China Pharma Holdings Inc.

China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.

Share on Social Networks: